Sight Sciences Announces the OMNI庐 Surgical System to be Included in UnitedHealthcare鈥檚庐 Expanded Coverage of Glaucoma Surgical Treatments
Sight Sciences (NASDAQ:SGHT) announced that UnitedHealthcare (UHC) will include its OMNI庐 Surgical System in its expanded coverage policy for glaucoma surgical treatments, effective October 1, 2025. The coverage applies to UHC's commercial and individual exchange benefit plans, reaching approximately 30 million of UHC's over 50 million total covered lives.
The policy covers procedures including goniotomy, trabeculotomy, canaloplasty, and combined procedures for adults with mild to moderate open-angle glaucoma. The FDA-cleared OMNI Surgical System is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open angle glaucoma, and can be performed before, during, or after cataract surgery.
Sight Sciences (NASDAQ:SGHT) ha annunciato che UnitedHealthcare (UHC) includer脿 il suo OMNI庐 Surgical System nella politica di copertura ampliata per i trattamenti chirurgici del glaucoma, a partire dal 1 ottobre 2025. La copertura si applica ai piani benefit commerciali e ai piani individuali dell'exchange di UHC, interessando circa 30 milioni delle oltre 50 milioni di persone coperte da UHC.
La politica copre procedure quali goniotomia, trabeculotomia, canaloplastica e procedure combinate per adulti con glaucoma ad angolo aperto da lieve a moderato. Il OMNI Surgical System, autorizzato dalla FDA, 猫 indicato per la canaloplastica seguita da trabeculotomia per ridurre la pressione intraoculare in pazienti adulti con glaucoma primario ad angolo aperto e pu貌 essere eseguito prima, durante o dopo la chirurgia della cataratta.
Sight Sciences (NASDAQ:SGHT) anunci贸 que UnitedHealthcare (UHC) incluir谩 su OMNI庐 Surgical System en su pol铆tica de cobertura ampliada para tratamientos quir煤rgicos del glaucoma, vigente a partir del 1 de octubre de 2025. La cobertura se aplica a los planes comerciales y a los planes individuales del mercado de UHC, abarcando aproximadamente a 30 millones de los m谩s de 50 millones de beneficiarios cubiertos por UHC.
La pol铆tica cubre procedimientos como goniotom铆a, trabeculotom铆a, canaloplastia y procedimientos combinados para adultos con glaucoma de 谩ngulo abierto de leve a moderado. El OMNI Surgical System, aprobado por la FDA, est谩 indicado para canaloplastia seguida de trabeculotom铆a para reducir la presi贸n intraocular en pacientes adultos con glaucoma primario de 谩ngulo abierto y puede realizarse antes, durante o despu茅s de la cirug铆a de cataratas.
Sight Sciences (NASDAQ:SGHT)電� UnitedHealthcare(UHC)臧� 鞛愳偓鞚� OMNI庐 Surgical System鞚� 雲闺偞鞛� 靾橃垹 旃橂鞐� 雽�頃� 頇曤寑霅� 氤挫灔 鞝曥眳鞐� 韽暔頃滊嫟瓿� 氚滍憸頄堨溂氅�, 須牓鞚� 2025雲� 10鞗� 1鞚�攵�韯办瀰雼堧嫟. 鞚� 氤挫灔鞚� UHC鞚� 靸侅梾鞖� 氚� 臧滌澑 甑愴櫂(鞚奠姢觳挫澑歆�) 氤错棙 頂岆灉鞐� 鞝侅毄霅橂┌, UHC臧� 氤挫灔頃橂姅 5,000毵� 氇� 鞚挫儊鞚� 頂茧炒項橃瀽 欷� 鞎� 3,000毵� 氇�鞐愱矊 順滍儩鞚� 鞝滉车頃╇媹雼�.
頃措嫻 鞝曥眳鞚� 臧�電犾垹(goniotomy), 彀嫧靹�(韸鸽澕氩犾卡搿滍啝氙�, trabeculotomy), 旃措偁搿滍攲霛检姢韹�(canaloplasty) 氚� 氤淀暕 鞁滌垹瓿� 臧欖潃 鞝堨皑毳� 瓴届鞐愳劀 欷戨摫霃勳潣 臧滊癌臧� 雲闺偞鞛レ潉 臧�歆� 靹膘澑鞐愱矊 鞝侅毄頃╇媹雼�. FDA 鞀轨澑霅� OMNI Surgical System鞚� 鞗愲皽 臧滊癌臧� 雲闺偞鞛レ潉 臧�歆� 靹膘澑 頇橃瀽鞚� 鞎堨晻鞚� 雮稊旮� 鞙勴暣 旃措偁搿滍攲霛检姢韹� 頉� 韸鸽澕氩犾卡搿滍啝氙胳棎 靷毄霅橂┌, 氚彪偞鞛� 靾橃垹 鞝劼缝路頉� 鞏胳牅霌� 鞁滍枆頃� 靾� 鞛堨姷雼堧嫟.
Sight Sciences (NASDAQ:SGHT) a annonc茅 que UnitedHealthcare (UHC) int茅grera son OMNI庐 Surgical System dans sa politique d'茅largissement de la couverture pour les traitements chirurgicaux du glaucome, 脿 compter du 1er octobre 2025. La couverture concerne les r茅gimes commerciaux et les plans individuels du march茅 d'UHC, atteignant environ 30 millions des plus de 50 millions de b茅n茅ficiaires couverts par UHC.
La politique couvre des proc茅dures telles que la goniotomie, la trab茅culotomie, la canaloplastie et les interventions combin茅es pour les adultes atteints de glaucome 脿 angle ouvert de l茅ger 脿 mod茅r茅. Le OMNI Surgical System, approuv茅 par la FDA, est indiqu茅 pour une canaloplastie suivie d'une trab茅culotomie afin de r茅duire la pression intraoculaire chez les patients adultes atteints de glaucome primitif 脿 angle ouvert, et peut 锚tre r茅alis茅 avant, pendant ou apr猫s une chirurgie de la cataracte.
Sight Sciences (NASDAQ:SGHT) gab bekannt, dass UnitedHealthcare (UHC) sein OMNI庐 Surgical System in die erweiterte Leistungspolicy f眉r glaukomchirurgische Behandlungen aufnimmt, wirksam ab dem 1. Oktober 2025. Die Deckung gilt f眉r UHCs kommerzielle Pl盲ne sowie f眉r Einzelversicherungspl盲ne des Exchanges und erreicht etwa 30 Millionen der insgesamt 眉ber 50 Millionen Versicherten von UHC.
Die Richtlinie umfasst Verfahren wie Goniotomie, Trabekulotomie, Kanaloplastik und kombinierte Eingriffe f眉r Erwachsene mit leichtem bis m盲脽igem Offenwinkelglaukom. Das von der FDA zugelassene OMNI Surgical System ist angezeigt f眉r eine Kanaloplastik gefolgt von einer Trabekulotomie zur Senkung des Augeninnendrucks bei erwachsenen Patienten mit prim盲rem Offenwinkelglaukom und kann vor, w盲hrend oder nach einer Kataraktoperation angewendet werden.
- Coverage expansion to 30 million UnitedHealthcare members
- Recognition of OMNI procedures as medically necessary
- Access to one of the largest US health insurance networks
- Validation of OMNI technology's clinical value
- None.
Insights
UnitedHealthcare's coverage of OMNI procedures significantly expands Sight Sciences' addressable market, boosting potential adoption and revenue.
This UnitedHealthcare policy update represents a significant commercial milestone for Sight Sciences. UHC's decision to cover procedures enabled by the OMNI Surgical System effectively opens access to approximately 30 million covered lives under their commercial and individual exchange plans. In the medical device sector, particularly for interventional technologies like OMNI, securing insurance coverage is often the critical gatekeeper to widespread clinical adoption.
The inclusion specifically covers goniotomy, trabeculotomy, canaloplasty, and combined procedures - precisely the interventions that OMNI enables for treating mild to moderate open-angle glaucoma. This coverage validation for implant-free MIGS procedures is particularly valuable as it positions OMNI as a clinically validated alternative to stent-based approaches in the growing minimally invasive glaucoma surgery market.
From a market perspective, UnitedHealthcare's status as one of the nation's largest insurers magnifies this development's importance. The October 1, 2025 effective date provides near-term visibility for potential revenue acceleration. Additionally, the coverage applies both to standalone procedures and those performed in conjunction with cataract surgery, maximizing the addressable patient population. The clinical recognition implied by this coverage decision - that these procedures are "proven and medically necessary" - should positively influence physician adoption patterns and potentially drive coverage decisions from other major payers.
UnitedHealthcare鈥檚 Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary
MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients鈥� lives, today announced that UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and combined canaloplasty (ab interno) and trabeculotomy procedures for adults (age 19 years or more), when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataract in adults currently being treated with ocular hypotensive medication.
This coverage policy, effective October 1, 2025, applies to UHC鈥檚 commercial and individual exchange benefit plans. UHC is one of the largest health insurance companies in the United States with over 50 million total covered lives. The commercial and individual exchange benefits plans currently cover approximately 30 million of the over 50 million total covered lives under UHC.
鈥淲e are pleased that UHC鈥檚 clinical review resulted in expanded coverage for implant-free, minimally invasive glaucoma surgery (MIGS) procedures, including OMNI, which is an important part of the glaucoma treatment paradigm,鈥� said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. 鈥淎s a result of this positive coverage policy, UHC鈥檚 members will have access to the OMNI technology when deemed medically necessary by their ophthalmologist.鈥�
The (OMNI) is FDA-cleared and indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure (IOP) in adult patients with primary open angle glaucoma. The procedure can be performed before, in combination with, or after cataract surgery.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients鈥� lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world鈥檚 most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company鈥檚 and are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm鈥檚 canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world鈥檚 leading cause of irreversible blindness. The is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company鈥檚 is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
Visit for more information.聽
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
UnitedHealthcare is a registered trademark of UnitedHealth Group Incorporated.
漏 2025 Sight Sciences. All rights reserved.
Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. These statements often include words such as 鈥渁nticipate,鈥� 鈥渆xpect,鈥� 鈥渟uggests,鈥� 鈥減lan,鈥� 鈥渂elieve,鈥� 鈥渋ntend,鈥� 鈥渆stimates,鈥� 鈥渢argets,鈥� 鈥減rojects,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渇orecast鈥� and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. These forward-looking statements include, but are not limited to, statements concerning the following: the effective date of the coverage policy and UHC members鈥� future ability to access the OMNI technology, and obtain coverage for procedures using the OMNI technology, when deemed medically necessary. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption 鈥淩isk Factors鈥� in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Media contact:
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
FAQ
When will UnitedHealthcare begin covering Sight Sciences' OMNI Surgical System?
How many UnitedHealthcare members will have access to SGHT's OMNI System?
What conditions is the OMNI Surgical System approved to treat?
What types of glaucoma procedures will UnitedHealthcare cover with OMNI?
When can the OMNI Surgical System be used in relation to cataract surgery?
